BioSpace News Archive

Cantargia Cantargia announced its interim report for the first quarter of 2024.

CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles using “click chemistry”, for targeting cancer cells.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE have announced that their collaboration to advance T cell receptor immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022.

So-Young International Inc. announced that it will report its financial results for the first quarter ended March 31, 2024, before U.S. markets open on May 28, 2024.

Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the Digestive Disease Week 2024 Annual Scientific Meeting.

Molecular Targeting Technologies, Inc., will update findings on both 177Lu-EBTATE clinical and 225Ac-EBTATE preclinical work during the 2024 SNMMI meeting in Toronto June 8-11.

CorDx announced a transformative $21M gift to the University of California San Diego’s Jacobs School of Engineering from CorDx founder Aiiso Yufeng Li, with support from members of the CorDx family – Li’s wife, Aiiso DongDong Li, Mac Chen, Haixia Yang, Monica Hu, and others at CorDx.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced its management will participate in fireside chats at the following upcoming conferences.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at ABGSC Investor Days in Stockholm on Thursday, May 23.

AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023.